A lawsuit filed Tuesday claims that, rather than protect patient access, the companies jacked up insulin prices in order to offer greater rebates to PBMs.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,